Evidence map›Paper›PMID 28040715›Full record

ArticleJournal of the National Comprehensive Cancer Network : JNCCN2017

Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.

Aparna Parikh, Chloe Atreya, W Michael Korn, Alan P Venook

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Comprehensive Cancer Network : JNCCN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Review
  7. Review
  8. Review
  9. Article
  10. Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress?Translational research : the journal of laboratory and clinical medicine · 2019
    Article
  11. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2018
    Review
  12. Article
  13. Role of ADAM10 in intestinal crypt homeostasis and tumorigenesis.Biochimica et biophysica acta. Molecular cell research · 2017
    Review
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Aparna ParikhFrom University of California San Francisco, Hellen Diller Family Comprehensive Cancer Center, San Francisco, California.
Chloe AtreyaFrom University of California San Francisco, Hellen Diller Family Comprehensive Cancer Center, San Francisco, California.
W Michael KornFrom University of California San Francisco, Hellen Diller Family Comprehensive Cancer Center, San Francisco, California.
Alan P VenookFrom University of California San Francisco, Hellen Diller Family Comprehensive Cancer Center, San Francisco, California.
Bristol-Myers Squibb (Germany) · DE

Funding

Targeting of Aberrant Signaling in Patient-Derived Colorectal Cancer ModelsK08CA175153 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ATREYA, CHLOE E. · 2013 to 2017
$867k
NCI NIH HHS K08 CA175153
6 · The paper itself

Abstract

HER2 gene amplifications and activating mutations in the HER2 receptor tyrosine kinase are present in 4% of metastatic colorectal cancers (mCRCs). HER2-targeted therapy is not standard of care, although preclinical and clinical data suggest that patients with HER2 amplifications and/or HER2-activating mutations may benefit from HER2-directed therapy. HER2 amplifications and activating mutations have also been implicated in resistance to anti-epidermal growth factor receptor-based therapy. This report describes a patient with KRAS, NRAS, and BRAF wild-type mCRC who experienced disease progression on first-line treatment with FOLFIRI and cetuximab after only 5 months, and subsequently experienced progression on second-line treatment with capecitabine and oxaliplatin plus bevacizumab after 2 months with significant functional decline. Next-generation sequencing of the primary tumor identified HER2 amplification, and we were able to obtain trastuzumab-DM1 for off-label use. The patient had symptomatic clinical benefit from trastuzumab-DM1 and had radiographic disease control for 7 months. On progression, therapy was changed to trastuzumab and pertuzumab, but the patient's disease progressed 3 months later. Treatment with the trastuzumab-DM1 resulted in a sustained response that was longer than his prior responses in the first and second lines of treatment, with a dramatic improvement in the patient's functional status. This case represents the first report, to our knowledge, of successful single-agent treatment of HER2-amplifed CRC with trastuzumab-DM1. Clinical trials targeting patients with HER2-mutated and -amplified metastatic colon cancer are currently underway. Molecular insights from investigating HER2 activation and the impact of HER2-directed therapies in a wide variety of solid tumors will create the needed evidence base to more broadly inform patient care.

Indexed as

Ado-Trastuzumab EmtansineAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBiopsyCamptothecinChemoradiotherapy, AdjuvantColorectal NeoplasmsDisease ProgressionDNA Mutational AnalysisDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesFluorouracilGene AmplificationHigh-Throughput Nucleotide SequencingHumansAdo-Trastuzumab EmtansineAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCamptothecinErb-b2 Receptor Tyrosine KinasesFluorouracilLeucovorinMaytansineMYC protein, humanProto-Oncogene Proteins c-mycTP53 protein, humanTrastuzumabTumor Suppressor Protein p53

Identifiers

PMID28040715
PMCPMC5564419
OpenAlexW2587699801

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.